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Background: Primary hyperparathyroidism (PHPT) is most commonly sporadic (sPHPT). However, sometimes PHPT
develops as part of multiple endocrine neoplasia (MEN) type 1 or 2A. In all, parathyroidectomy is the only curative
treatment. Nevertheless, there are important differences in clinical expression and treatment.
Methods: We analyzed a consecutive cohort of patients treated for sporadic, MEN1-related, and MEN2A-related
PHPT and compared them regarding clinical and biochemical parameters, differences in preoperative workup,
operative strategies, findings, and outcome.
Results: A total of 467 patients with sPHPT, 52 with MEN1- and 16 with MEN2A-related PHPT were analyzed.
Patients with sPHPT were older, more often female and had higher preoperative calcium and parathyroid hormone
levels, when compared with MEN1 and MEN2A patients. Minimally invasive parathyroidectomy (MIP) was performed
in 367 of 467 sPHPT patients (79%). One abnormal parathyroid was found in 426 patients (91%). Two or more in 35
patients (7%). In six patients (1%) no abnormal parathyroid gland was retrieved. Of 52 MEN1 patients, eight (15%)
underwent a MIP and 44 patients (85%) underwent conventional neck exploration (CNE); with resection of fewer
than 3½ enlarged glands in 21 patients (40%), subtotal parathyroidectomy (SPTX, 3-3½ glands) in seventeen (33%)
and total parathyroidectomy with autotransplantation (TPTX) in six (12%). Eleven patients (21%) had persistent
disease, 29 (56%) recurrent PHPT and nine (17%) permanent hypoparathyroidism, mostly after TPTX. Of 16 MEN2A
patients, six (38%) underwent MIP, four (25%) CNE and six (38%) selective resection of the enlarged gland(s) during
total thyroidectomy. Three patients (19%) suffered from persistent PHPT and two (13%) developed recurrent
disease.
Conclusions: Sporadic PHPT, MEN1- and MEN2A-related PHPT are three distinct entities as is reflected
preoperatively by differences in gender, age at diagnosis and calcium and PTH levels.
MEN2A patients are very similar to sPHPT with respect to operative approach and findings. MIP is the treatment of
choice for both. MIP has low rates of persistent and recurrent PHPT and a low complication rate. The percentage of
multiglandular disease and recurrences are significantly higher in MEN1 patients, demonstrating the need for a
different approach. We advocate treating these patients with CNE and SPTX.
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The etiology of primary hyperparathyroidism (PHPT), a
common endocrine disease, is most frequently sporadic
and non-familial (sPHPT) [1]. A significant proportion of
patients, however, develop PHPT as part of the familial
syndromes multiple endocrine neoplasia (MEN) type 1 or
2A [2,3]. Major features of MEN1 are endocrine tumors of
the parathyroid, pituitary, and pancreas. Minor features
consists of bronchial and thymic tumors [4,5]. MEN2A is
associated with medullary thyroid cancer, PHPT, and pheo-
chromocytoma [6]. In all cases of PHPT, parathyroidectomy
is the only curative treatment that resolves symptoms and
metabolic complications and thus improves quality of life,
in both symptomatic and asymptomatic patients.
Clinical features that differentiate between patients
with sporadic PHPT and MEN-related PHPT are: age of
onset, female to male ratio, severity of bone involvement,
family history and related endocrine neoplasias [7-9]. Once
PHPT and its setting are diagnosed, the course of the
disease and its treatment will change the perspective for
both surgeon and patient considerably.
However, most of the current literature analyzes data
on surgical treatment of PHPT without making any such
distinction to this profound difference in etiology [9-11].
Although hypercalcemia might be the first clinical par-
ameter to be discovered in all three, we strongly believe,
these are very distinct and different entities, requiring a
different approach.
In a population based cohort of patients treated for
PHPT, we evaluated the frequency and causes (number of
affected glands) of sporadic, MEN1- and MEN2A-related
PHPT, as well as the differences in their clinical presenta-
tion, preoperative workup and operative strategies, findings
and outcome. We sought to determine whether, with
optimal surgical strategies for each subgroup, a comparable
outcome (low persistent and recurrence rates) with equally
low complication rates (hypoparathyroidism and recurrent
laryngeal nerve injury) could be obtained.
Patient and methods
We retrospectively analyzed the records of a consecutive
cohort of patients treated for sPHPT in one geographical
region of The Netherlands between 1994 and 2009,
comprising one academic center and three affiliated
hospitals. All patients were symptomatic. The diagnosis
PHPT was established biochemically by a serum calcium
level greater than 10.20 mg/dL (>2.55 mmol/L) and/or
a serum ionized calcium greater than 5.28 mg/dL
(>1.32 mmol/L) combined with an increased, greater
than 65 pg/mL (>6.5 pmol/L), or not suppressed
plasma parathyroid hormone (PTH) level. In a few
patients calcium levels were normal, but an increased renal
calcium excretion combined with an elevated PTH level
was affirmative for PHPT [12-14]. In addition, all patientswith PHPT from the MEN1 and MEN2 database at the
University Medical Center Utrecht (UMCU), The
Netherlands were analyzed. The MEN1 database includes
patients diagnosed with PHPT between 1967 and 2009.
Patients were included in the MEN1 database if they had
genetically proven MEN1, or three out of five manifesta-
tions of MEN1 or one out of five manifestations and a first-
degree family member. Gene testing (mutation analysis)
was performed in very young patients with PHPT, PHPT in
combination with possible MEN1 manifestations, or a
MEN- positive family history [15]. From the MEN2
database, patients diagnosed with PHPT between 1979 and
2009 were selected. MEN2A was defined in case of a
MEN2A germline mutation. Patients with MEN1 and
MEN2A were included if they had biochemical evidence of
PHPT as stated above or enlarged parathyroid glands while
undergoing a total thyroidectomy. Since the UMCU is a
tertiary referral center, also patients who were initially
treated at another institution and later referred to our
institution were included. All patients gave ethical consent
for their information to be held anonymously in our data-
base and to be used for future retrospective analysis.
Preoperative localizing studies were used in sPHPT
and MEN2A patients and included ultrasonography
(US), computed tomography (CT) and/or technetium-
99m-sestamibi-scintigraphy (MIBI). The preoperative
diagnostic work up differed between hospitals and evalu-
ated over time. Presently, our preferential preoperative
work up consists of MIBI and US. Depending on the
results of the preoperative localization studies, sPHPT
and MEN2A patients were subsequently operated in a
preferentially minimally invasive approach [16]. MIP
was defined as a small (3cm) incision over the
suspected adenoma as guided by preoperative localization
(two concordant preoperative imaging techniques),
whereas a unilateral approach involves a larger incision
and exposure plus systematic exploration of the entire area
of interest on one side (based on one positive preoperative
imaging). Both inferior and superior parathyroid glands
will have to be identified using this approach. In case of no
visualization of an enlarged gland or discordant imaging
techniques a conventional neck exploration (CNE) was
performed. Preoperative imaging for MEN1 patients is not
part of our policy, although many patients underwent
preoperative imaging studies prior to referral to our
surgical department. In subtotal parathyroidectomy
(SPTX), 3–3½ parathyroid glands were resected during
a CNE after identification of all parathyroid glands. In
total parathyroidectomy (TPTX), four glands were
resected and one (partial) gland was used as a graft for
autotransplantation into the brachioradial muscle of
the nondominant forearm. The autotransplantation
was performed during the same operation, using fresh
parathyroid tissue.
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intraoperative frozen section analysis, to verify removal of
aberrant parathyroid tissue, were carried out in a routine
fashion whenever a minimally invasive parathyroidectomy
(MIP) was performed. A significant drop of more than
50% from the highest of either preoperative baseline or
preexcision level at 10 minutes after hyperfunctioning
parathyroid gland(s) excision indicates surgical cure and
predicts postoperative normocalcemia [17,18].
Surgical cure was defined as a normalization of serum
(ionized) calcium and PTH levels for a period of at least
six months after the surgical procedure. Persisting
hypercalcemia or renewed hypercalcemia within the first
six months after surgery was considered indicative of
surgical failure. Hypercalcemia after a period of six month
of postoperative normocalcemia was defined as recurrent
disease. The findings of all operations necessary to achieve
normocalcemia were taken into account when determining
the cause of PHPT. Extirpation of a single enlarged
parathyroid gland with subsequent normalization of
serum calcium was defined as single gland disease.
Retrieval of more than one enlarged parathyroid gland
leading to normocalcemia was defined as multiglandular
disease (MGD). Multiglandular hyperplasia was defined
as the situation when all four glands appeared abnormal.
Hypoparathyroidism and nerve damage were considered
complications of surgery. Permanent hypoparathyroid-
ism was defined as a serum ionized calcium of less than
4.60 mg/dL (<1.15 mmol/L) and/or total calcium of less
than 8.48 mg/dL (<2.12 mmol/L), persisting beyond the
first six months after surgery and requiring substitution
with calcium and an active form of vitamin D.
To get insight into PHPT in MEN1 and MEN2A and
their difference with respect to sPHPT, we evaluated clin-
ical and biochemical parameters, differences in preoperative
workup, operative strategies, and findings.
All continuous variables were reported as median (range).
Mann–Whitney U test and Independent-Samples T
Test were used for two-group comparison of continuous
variables and Chi squared test for analysis of categorical
data. Statistical analysis was performed using SPSS version
15.0 (SPSS, Inc., Chicago, IL). Statistical significance was
established at p<0.05.
Results
A total of 535 patients were analyzed. The cohort consists
of 467 patients with sPHPT, 52 with MEN1- and 16 with
MEN2A-related PHPT. Patient characteristics are summa-
rized in Table 1. Gender, age, preoperative calcium and
PTH levels were significantly different among groups. In
the sPHPT group, there were more females, patients were
older and preoperative calcium and PTH levels were
higher compared with the MEN1 and MEN2A patients
(p<0.001 Chi2, p<0.001 Independent-Samples T Test andp=0.012 Mann–Whitney U test, respectively). Clinical
complaints as lethargy and renal stones were not signifi-
cantly different between sPHPT patients and MEN1 and
MEN2A patients (p=0.184 and p=0.06 versus p=0.22 and
p=0.59 Chi2, respectively).
The average number of preoperative imaging was similar
in the sPHPT and MEN2A group (mean number of used
imaging modalities 1.97 and 1.63 respectively), but higher
when compared with MEN1 patients (mean number of
used imaging modalities 1.06).
The operative findings and postoperative course, as
well as the complications for each group are described
in Tables 2 and 3.
sPHPT
Of 467 patients with sPHPT, treated in the UMCU or in
one of three regional teaching hospitals, 367 patients
(79%) were scheduled for a MIP. The remaining 100
patients underwent a planned CNE. In 39 patients (8%) a
MIP procedure was intraoperatively converted to a CNE.
In 18 of these patients, the minimal invasive approach
provided insufficient exposure to enucleate a correctly
localized adenoma. In one patient the adenoma was not
found. In the other 20 patients, the preoperative imaging
was not consistent with the intraoperative findings. The
surgical success rate after primary surgery was 93%
(n=435). Hypercalcemia persisted after the first operation
in 31 patients (7%). The persistence rate in patients with
IOPTH measurement was 4%. The cumulative surgical
success rate, including an early second operative proced-
ure, was 99% (n=461). Normocalcemia resulted from
removing one abnormal parathyroid gland in 426 patients
(91%). Two or more abnormal glands were removed in 35
patients (7%), while four gland hyperplasia was the
observed cause of PHPT in one patient. In six patients
(1%) no abnormal parathyroid gland was retrieved and
thus hypercalcemia persisted. Four patients developed
recurrent hypercalcemia. Parathyroid carcinoma was
diagnosed in four patients. The median follow-up was
two years (range 1–15 years). Three patients sustained
permanent recurrent laryngeal nerve damage and one
patient became permanent hypocalcemic.
MEN1
Fifty-two patients underwent primary surgery for PHPT
either at the UMCU (n=36) or another affiliated hospital
(n=16). Eight patients (15%) underwent a MIP, twenty-
one underwent less than SPTX (<SPTX), seventeen
underwent SPTX and six underwent TPTX. In three
patients a MIP procedure was intraoperatively converted
to a CNE and TPTX due to inadequate drop of IOPTH
levels. Eleven patients (21%) had persistent disease; nine
patients after <SPTX (31%), one after SPTX (7%) and one
after TPTX (17%). Twenty-eight patients (54%) developed
Table 2 Surgery for Primary Hyperparathyroidism in Sporadic, MEN1 and MEN2A
Characteristics Sporadic pHPT, n = 467 MEN1-pHPT, n = 52 MEN2A-pHPT, n = 16
Initial operation, n
Minimally invasive parathyroidectomy 328 (70%) 5 (10%) 6 (38%)
Minimally invasive parathyroidectomy converted to
conventional neck exploration
39 (8%) 3 (6%) 0
Conventional neck exploration 100 (21%) 44 (84%) 10 (62%)
Subtotal parathyroidectomy, n - 38 (73%) -
Total parathyroidectomy, n - 6 (12%) -
Number of operations, n
One procedure 435 (93%) 26 (50%) 13 (81%)
Two procedures 31 (7%) 17 (33%) 1 (6%)
Three or more procedures 1 (<1%) 9 (17%) 2 (13%)
Mean number of operations 1.07 1.85 1.29
Cumulative operative findings, n
No adenoma found 6 (1%) - 1 (6%)
1 enlarged gland 426 (91%) 17 (33%) 13 (81%)
Solitary (adenoma, hyperplasia) 422 (90%) 17 (33%) 13 (81%)
Carcinoma 4 (1%) - -
> 1 enlarged glands 35 (7%) 35 (56%) 2 (13%)
2 enlarged glands 26 (6%) 12 (23%) 2 (13%)
3 enlarged glands 8 (2%) 17 (33%) -
> 3 enlarged glands or hyperplasia 1 (<1%) 6 (12%) -
Abbreviations: pHPT, primary hyperparathyroidism; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A. Subtotal
parathyroidectomy; (less than) SPTX. Total parathyroidectomy; TPTX.
Table 1 Characteristics of Primary Hyperparathyroidism in Sporadic, MEN1 and MEN2A Patients
Characteristics Sporadic pHPT, n = 467 MEN1-pHPT, n = 52 MEN2A-pHPT, n = 16
Female, n 357 (76%) 33 (63%) 9 (56%)
Age, y, median (range) 63 (20 to 88) 33 (11 to 62) 39 (20 to 66)
Symptoms at first presentation, n 467 (100%) 42 (81%) 12 (75%)
Fatigue 188 (40%) 16 (31%) 4 (25%)
Renal stones 115 (25%) 14 (27%) 3 (19%)
Osteoporosis 73 (16%) 0 4 (25%)
Gastrointestinal symptoms 67 (14%) 7 (14%) 0
Neuropsychiatric 42 (9%) 7 (14%) 1 (6%)
Preoperative serum level, mean (range)
Ionized calcium, mg/dL 6.76 (4.60 to 7.40) 5.56 (4.44 to 6.44) 5.4 (5.32 to 5.68)
Calcium, mg/dL 11.56 (10.12 to 22.20) - -
Parathyroid hormone, pg/mL 219 (10 to 3097) 78 (16 to 191) 89 (52 to 249)
Imaging modality, n
Ultrasonography 399 (85%) 30 (57%) 10 (63%)
Computed tomography 317 (68%) 13 (25%) 8 (50%)
Technetium-99m-sestamibi-scintigraphy 206 (44%) 12 (23%) 8 (50%)
Number of used imaging modalities, mean 1.97 1.06 1.63
Abbreviations: pHPT, primary hyperparathyroidism; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A.
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Table 3 Outcome of Surgery for Primary Hyperparathyroidism in Sporadic, MEN1 and MEN2A
Characteristics Sporadic pHPT, n = 467 MEN1-pHPT, n = 52 MEN2A-pHPT, n = 16
Persistent disease, n
After first procedure 31 (7%) 11 (21%) 3 (19%)
After second procedure 6 (1%) 4 (8%) 1 (6%)
Recurrent disease, n
After first procedure 3 (<1%) 28 (54%) 2 (13%)
After second procedure - 12 (24%) 1 (6%)
Complications, n
Recurrent laryngeal nerve injury 3 (<1%) 1 (2%) 1 (6%)
Hypocalcemia 1 (<1%) 10 (19%) 2 (13%)
Abbreviations: pHPT, primary hyperparathyroidism; MEN1, multiple endocrine neoplasia type 1; MEN2A, multiple endocrine neoplasia type 2A.
Twigt et al. Orphanet Journal of Rare Diseases 2013, 8:50 Page 5 of 8
http://www.ojrd.com/content/8/1/50recurrent PHPT, after a median time to recurrence of 8.0
years after <SPTX (56%), and after a median time of
13.0 years after SPTX (65%). None of the patients who
underwent TPTX had recurrence. After primary surgery,
ten patients (19%) developed permanent hypoparathyroid-
ism; 7% after <SPTX, 25% after SPTX and 67% of the pa-
tients who underwent TPTX. One patient had a permanent
recurrent laryngeal nerve injury, after multiple operations
for persistent and recurrent PHPT.
MEN2A
Sixteen MEN2A patients underwent primary surgery for
parathyroid disease between 1979 and 2010. Eleven
operations were carried out at the UMCU and five in
affiliated hospitals. Ten patients were operated in varying
years after a previous total thyroidectomy. Six patients of
these underwent MIP and four patients underwent CNE
(n=3 one gland resected, n=1 two glands resected). In the
other six patients selective resection of the enlarged gland
(s) was performed during total thyroidectomy for medul-
lary thyroid carcinoma (n=1 no glands resected because
none were found, n=4 one gland resected, n=1 two glands
resected). None of our MEN2 patients underwent a para-
thyroidectomy before they underwent a thyroidectomy.
Thirteen patients were initially cured after the primary
operation. Three patients suffered from persistent
PHPT, two patients developed recurrent disease. The
mean overall follow-up after primary surgery was 9 years
(range 5–27 years). After MIP, one patient had persistent
PHPT, but no one developed recurrent PHPT during five
years of follow-up. Five patients had hypoparathyroidism,
due to inadvertent damage to parathyroid glands during
total thyroidectomy.
The percentage of operations started as a minimally
invasive operation was higher in the sPHPT group when
compared with the MEN populations (p <0.001, chi2).
The average number of operations was higher in MEN
patients when compared with the sPHPT population
(p<0.001, chi2); between MEN1 and MEN2A we couldnot demonstrate a significant difference. The number of




According to our study and previous literature, sporadic
PHPT, MEN1- and MEN2A-related PHPT are three
distinct entities as is reflected preoperatively by differences
in gender, age at diagnosis, and preoperative calcium
and PTH levels [7-9]. Clearly this leads to a distinct
algorithm regarding the preoperative workup and
operative strategy (Figure 1). We found no difference
in the prevalence of clinical symptoms, in agreement
with previous studies [9,19].
Our data compared wtih the literature
sPHPT
As others have demonstrated operative findings may be
a function of the operative approach; a CNE leads to
removal of more parathyroid glands and thus a higher
percentage of multiglandular disease [20,21]. In our
series the frequency of solitary adenomas observed is
higher than historically reported [22]. The extent of the
preoperative workup influences the number of observed
solitary adenomas. In case of two concordant imaging
studies we advocate to perform a MIP, if there is only
one positive study a unilateral exploration and if all
imaging studies are negative or contradictive an upfront
CNE. The use of IOPTH remains controversial and we
advise not to use it in a routine fashion [23-29]. Others,
however ,do show benefits of IOPTH measurement
[30-32]. Especially, in patients with recurrent disease, in
patients with proven or suspected multiglandular disease,
as well as in patients with inconsistent preoperative
imaging, IOPTH can add to decision making and improve
outcome [33-35]. We included some patients with a
normal calcium level. One might argue whether in these
patients PHPT can be diagnosed. However, pathology
Patient with PHPT
Possible preoperative factors to differentiate between sporadic, MEN1- and MEN2A-PHPT
age
calcium levels
family history, genetic information
associated syndrome features
sPHPT MEN1 MEN2A
MIBI and US No imaging MIBI and US
MIP, Unilateral
NE or CNE 
depending on 
imaging
CNE MIP, Unilateral 
NE or CNE 
depending on 
imaging
Only excision of 
enlarged gland(s)
Excision of 3-3 ½ 
glands
Only excision of 
enlarged gland(s)
Figure 1 Treatment algorithm for patient with PHPT. PHPT primary hyperparathyroidism, MEN1 multiple endocrine neoplasia type 1, MEN2A
multiple endocrine neoplasia type 2A, sPHPT sporadic primary hyperparathyroidism, MIBI technetium-99m-sestamibi-scintigraphy, US ultrasound,
MIP minimally invasive parathyroidectomy, NE neck exploration, CNE conventional neck exploration.
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patients might only be intermittent normocalcemic or
become asymptomatic patients later. Furthermore there is
some evidence for a generalized target-tissue resistance to
parathyroid hormone and as a result a renal tubular
resistance to the action of PTH and thus increased
renal calcium excretion [12-14].
MEN1
The percentage of MGD is significantly higher in MEN1
patients, this demonstrates the need for a different
approach in this category of patients. Ninety-five percent
of MEN1 patients were treated with a CNE. Some
advocate to perform a TPTX [36-38]. Based on the data
presented by the DutchMEN1 Study Group, who reported
a genotype-phenotype correlation in MEN1-related PHPT,
we have changed our surgical strategy over the last years.
Part of the patients in the present study was included in thepatient cohort of a previous study. Recurrence after <SPTX,
in this cohort, was significantly lower in patients with non-
sense or frameshift mutations in exon 2,9, and 10. This in-
dicates that cure primarily depends on the amount of
parathyroid tissue removed. As these results have to be
confirmed in an independent patient population, we have
not repeated this analysis in the present cohort [5]. Because
TPTX frequently results in hypoparathyroidism [38-45],
SPTX combined with bilateral transcervical thymectomy is
now the preferred procedure in our institution, providing
the best balance between cure and postoperative hypopara-
thyroidism [5,46]. When taken the high number of CNE
into account we found the number of used imaging mo-
dalities in the MEN1 group rather high. A plausible cause
might be the unawareness of referring physicians with the
possibility of MEN-related PHPT and the inability to
localize a solitary gland at first presentation causing more
extensive preoperative imaging.
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Despite different patient characteristics, MEN2A patients
are very similar to patients with sPHPT with respect to
their operative approach and intraoperative findings. A fo-
cused MIP is therefore the treatment of choice for PHPT
in MEN2A patients [47]. MIP has low rates of persistent
and recurrent PHPT and the complications are minimal.
Especially patients treated in more recent years have equal
rates of solitary and multiglandular disease.
Weaknesses and strengths
Weaknesses of our study are the fairly large differences
in the number of sporadic, MEN1- and MEN2A-related
PHPT patients and the time period in which they were
treated. Unfortunately, due to the rarity of MEN
syndromes these differences are inevitable. Furthermore,
treatment of all three categories has gradually changed
over the years due to more refined preoperative
localization techniques, IOPTH measurement and the
growing awareness and understanding of their differ-
ences in pathophysiology and genotype. This implies a
heterogeneous case mix. On the other hand, this does
reflect the clinical practice over the past decades in
many hospitals and countries. A potential confounding
factor is the location of treatment. The majority of MEN
patients were treated in a tertiary referral center,
whereas (50%) of the sPHPT patients were treated in an
affiliated hospital. However, preoperative imaging and a
preferentially minimally invasive approach was the
standard of care in all four hospitals. Many studies have
focused on patients with sporadic and MEN-related
PHPT separately. The strength of this study is the
description of both phenotype, preoperative work up
and surgical strategy in all three categories; offering a
complete overview and a treatment algorithm.
Conclusion
We performed a descriptive case–control study in which
the different outcomes for sporadic, MEN1- and MEN2A-
related primary hyperparathyroidism were assessed and
possible contributing confounding factors were analyzed.
In light of our findings in these three categories of
patients; i.e. the significant higher number of MGD,
reoperation rate and percentage of recurrent disease in
MEN1 patients we advocate the treatment algorithm as
outlined in Figure 1. In our opinion these findings are a
corroboration to concentrate and treat MEN patients in a
tertiary referral center.
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